In Profile: The Top Ten Players in Medical Equipment and Supplies Market

Pharma IQ
Posted: 07/19/2011

Pharma IQ provides you with a quick update of the activities of the Top 10 players in medical equipment and supplies market in 2011. Figures according to Forbes The World Biggest Companies.

1. Johnson & Johnson   Sales of $61.6 billion
CEO William C Weldon

Johnson & Johnson has signalled its commitment to the emerging markets of Asia this year with the opening of an innovation centre in China, encompassing a number of its medical device units.

Michael del Prado, company group chairman for Johnson & Johnson Medical Companies in Asia Pacific, said the centre will focus on developing devices for diseases prevalent in Asia Pacific, creating products designed for use in rural settings and manufacturing more economical multi-use and disposable products.

2. Medtronic   Sales of $15.8 billion
CEO Omar Ishrak

Medtronic has made two recent acquisitions within the field of surgical products, entering into definitive agreements with both PEAK Surgical and Salient Surgical Technologies.

Salient, a leader in the advanced energy category for haemostatic sealing of soft tissue and bone for a number of surgeries, was acquired for $525 million and is intended to bring "new applications to Medtronic Surgical Technologies' current surgical therapy areas".

PEAK, which was acquired for $120 million, works in the emerging field of advanced energy surgical incision technology, with innovations cleared for use in a variety of surgeries.

3. Fresenius   Sales of $21.4 billion
CEO Rainer Baule

Fresenius entered 2011 on the back of record sales in 2010 and has so far reported strong sales and earnings growth.

The group's Kabi business, one of the leading producers of medical devices, said it has seen a strong start in North America, thanks to successful product launches.

Fresenius Medical Care also recently completed the acquisition of Euromedic's dialysis service business, subject to final regulatory approval.

4. Baxter International   Sales of $12.8 billion
CEO Walter E Boomer

Baxter International exceeded guidance with its first quarter results, with a 20 per cent increase in sales of medical products. "Double-digit growth in the IV Therapies and Global Injectables product categories" was said to be one of the main drivers behind this rise.

The Medical Products business was only formed in October 2010, with the joining of the Renal and Medication Delivery businesses.

5. Covidien   Sales of $10.6 billion
CEO José E Almeida

Covidien has continued its work in the spine sealant category this year, receiving approval from the United States Food and Drug Administration (FDA) for DuraSeal Exact spine sealant.

The company launched its original DuraSeal spine sealant in 2009, the only spin sealant to have gained approval from the FDA. The new Exact product was shown to cause decreased post surgery swelling than its predecessor.

6. Stryker   Sales of $7.3 billion
CEO Stephen P MacMillan

Stryker has been keen to show its resilience in the face of tough conditions for the orthopaedics industry, having already lined up $2 billion in acquisitions this year, a huge increase in what it spent pre-recession, Med City reported.

The company also received a boost to its products with a report from National Joint Registry for England and Wales, which said Stryker's TridentCup, AccoladeHip Stem and Triathlon Knee System outperformed the most frequently used brands in terms of revision rates.

7. Becton, Dickinson   Sales of $7.3 billion
CEO Edward Ludwig

Becton, Dickinson has been calling attention to its R&D spending this year, having achieved an 8.5 per cent year-on-year increase in revenues outside of the United States, thanks to the strength being seen in emerging marks.

BD's manufacturing plant in Fukushima experienced some damage from the earthquake, with full manufacturing expected to recommence in the third quarter of 2011.

8. St Jude Medical   Sales of $5.2 billion
CEO Daniel J Starks

St Jude Medical has been making strides with its medical devices for patients with heart conditions. The company gained approval in Japan for its Fortify(TM) ST implantable cardioverter defibrillators (ICD) and Unify(TM) cardiac resynchronisation therapy defibrillator, the smallest in the industry.

Surgeons also completed the first human transplant of the Portico transcatheter valve, which could potentially help 400,000 patients worldwide.

9. Synthes   Sales of $4.1 billion
CEO Michel Orsinger

In April, Synthes merged with Johnson & Johnson to form the "most innovative and comprehensive orthopaedics business in the world".

The $21.3 billion deal is intended to allow the two companies to better access the $37 billion global market for orthopaedics.

10. Boston Scientific   Sales of $7.8 billion
CEO J. Raymond Elliott

Boston Scientific announced it is to lose chief executive Ray Elliot at the end of 2011, who oversaw the creation of a more robust internal pipeline at the company.

The firm now has more than 150 internal R&D initiatives underway, twice the figure in place in 2009, and is directing 30 percent of its R&D budget to growth projects in 2011.


Pharma IQ
Posted: 07/19/2011

Pharma IQ Members

EVENTS OF INTEREST

Crowne Plaza Zurich, Zurich, Switzerland
June 17 - 19, 2018